Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD69 | Q07108 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.53 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.53 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.53 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15960454 | 1.00 | CD69 (0.61) | CD69ALDH1A1THRBMAPK1LGALS8 | |
| SCHEMBL18061241 | 1.00 | CD69 (0.61) | CD69ALDH1A1THRBMAPK1LGALS8 | |
| SCHEMBL13004026 | 1.00 | CD69 (0.61) | CD69ALDH1A1THRBMAPK1LGALS8 | |
| SCHEMBL19726096 | 1.00 | CD69 (0.61) | CD69ALDH1A1THRBMAPK1LGALS8 | |
| SCHEMBL13452662 | 1.00 | CD69 (0.61) | CD69ALDH1A1THRBMAPK1LGALS8 | |
| SCHEMBL15935719 | 1.00 | CD69 (0.61) | CD69ALDH1A1THRBMAPK1LGALS8 | |
| SCHEMBL2629594 | 1.00 | CD69 (0.61) | CD69ALDH1A1THRBMAPK1LGALS8 | |
| SCHEMBL16187917 | 1.00 | CD69 (0.61) | CD69ALDH1A1THRBMAPK1LGALS8 | |
| SCHEMBL13663174 | 0.92 | CD69 (0.61) | CD69ALDH1A1THRBMAPK1LGALS8 | |
| SCHEMBL13541613 | 0.92 | CD69 (0.61) | CD69ALDH1A1THRBMAPK1LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202469-B2 | Sugar chain-attached linker, compound containing sugar chain-attached linker and physiologically active substance or salt thereof, and method for producing same | GLYTECH, INC. (KP) | 2019-02-12 | — | — | US | disclosed |
| US-9879097-B2 | Method for producing activated sugar chain derivative and activated sugar chain derivative produced therefrom | GLYTECH, INC. (JP) | 2018-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202469-B2 | Sugar chain-attached linker, compound containing sugar chain-attached linker and physiologically active substance or salt thereof, and method for producing same | SI, ENGASE, DNPEP | CD69 705/4885ALDH1A1 886/4885THRB 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.